Loading...

Wuhan YZY Biopharma Co Ltd

2496.HK•HKSE
Healthcare
Biotechnology
HK$5.20
HK$0.25(5.05%)

Wuhan YZY Biopharma Co Ltd (2496.HK) Stock Overview

Explore Wuhan YZY Biopharma Co Ltd’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 59.8/100

Key Financials

Market Cap1B
P/E Ratio-5.07
EPS (TTM)$-0.55
ROE-3.00%
Fundamental Analysis

AI Price Forecasts

1 Week$4.23
1 Month$4.76
3 Months$3.06
1 Year Target$4.49

2496.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Wuhan YZY Biopharma Co Ltd (2496.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 64.59, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $4.49.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -5.07 and a market capitalization of 1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

64.59RSI (14)
0.05MACD
30.14ADX
Stats data is not available for 2496.HKStats details for 2496.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 2496.HKAnalyst Recommendations details for 2496.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma and other advanced solid tumors, small cell lung cancer, relapsed/refractory multiple myeloma, and HER2-positive solid tumors; and covid 19 indication, as well as wAMD, DME, and other ocular neovascularization-related diseases. The company was founded in 2010 and is based in Wuhan, China.

CEO

Pengfei Zhou

Employees

113

Headquarters

Building C2-1, Optics Valley Biocity, Wuhan

Founded

2023

Frequently Asked Questions

;